ESMO 2023 | Promising insights into neuro-oncology at ESMO 2023

Enrico Franceschi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, discusses his highlights in neuro-oncology from ESMO 2023. With increasing interest in immunotherapy, novel agents and biomarkers, the future of glioma treatments is bright. The Phase III INDIGO (NCT04164901) trial has shown the novel IDH inhibitor vorasidenib to be effective in treating low-grade gliomas, with the potential to influence the standard treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.